Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-10-21
1998-06-09
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 77, A61K 3158
Patent
active
057633614
ABSTRACT:
The novel compounds of the present invention are those of structural formula I: ##STR1## or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5.alpha.-reductase, particularly 5.alpha.-reductase type 1. The compounds of formula I are useful in the systemic, including oral, or parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia which includes female and male pattern baldness, female hirsutism, benign prostafic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as in the treatment of prostatitis. Methods of using the compounds of formula I for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis are provided, as well as pharmaceutical compositions for the compounds of formula I. The use of compounds of formula I in combination with other, active agents, for example with a 5.alpha.-reductase type 2 inhibitor such as finasteride or epristeride, or a potassium channel opener, such as minoxidil, or a retinoic acid or a derivative thereof is also taught, wherein such combinations would be useful in one or more of the above-mentioned methods of treatment or pharmaceutical compositions.
REFERENCES:
patent: 3239417 (1966-03-01), Di Tullio et al.
patent: 3264301 (1966-08-01), Doorenbos et al.
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5237064 (1993-08-01), Bakshi et al.
patent: 5359071 (1994-10-01), Durette et al.
patent: 5470976 (1995-11-01), Humphrey et al.
patent: 5494914 (1996-02-01), Labrie
patent: 5512555 (1996-04-01), Waldstreicher
patent: 5516779 (1996-05-01), Von Langen et al.
patent: 5527807 (1996-06-01), Bakshi et al.
patent: 5543417 (1996-08-01), Waldstreicher
patent: 5585383 (1996-12-01), Forman et al.
patent: 5658922 (1997-08-01), Durette et al.
Back et al., Can. J. Chem. 69 (1991), pp. 1482-1486, "The synthesis of some novel N-chloro-delta1-4-azasteroids by efficient N-chlorination of azasteroid lactams . . . ".
Rasmusson et al., J. Med. Chem. 27 (1984), pp. 1690-1701, "Azasteroids as inhibitors of rat prostatic 5alpha-reductase".
Back et al., J. Org. Chem. 54 (1989), pp. 1904-1910, "N-Chloroazasteroids: A novel class of reactive steroid analogues".
Brooks et al., Steroids 47/1 (1986), pp. 1-19, "5alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat".
The Daily, Tuesday, May 7, 1996, "New data on Proscar, Abbotts's Hytrin show conflicting results".
Wall Street Journal, May 7, 1996, p. B4, "Study finds Abbott's prostate drug is much more effective than Merck's".
Boyle et al., Urology 48:398-405, 1996, "Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride".
Diani et al J. Clin. Endocrin. and Metab. vol. 55 No. 1 pp. 345-350, 1990.
Heluker, Wall St. Jour. pp. A1, A7, 7 Jun. 1991.
Stinson Chem and Eng News, Jun. 29, 1992 pp. 7-8.
Harris Georgianna
Sahoo Soumya P.
Tolman Richard L.
Daus Donald G.
Fitch Catherine D.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
17-alkyl-7-substituted-4-aza steroid derivatives as 5-.alpha.-re does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17-alkyl-7-substituted-4-aza steroid derivatives as 5-.alpha.-re, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17-alkyl-7-substituted-4-aza steroid derivatives as 5-.alpha.-re will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2198879